Category Archives: Biotechnology

Thailand is looking forward to co-operate with Cuba on biotechnology which could bring changes in food and herbal studies. Both the countries have entered into an agreement on scientific co-operation in the areas of nanotechnology, biotechnology, computer and electronics and materials science. The agreement would enable Thailand to gain from knowledge of Cuba since Cuba is quite advanced in the field of biotechnology as it’s quite rich in biological resources. Prime minister of Thailand is on a visit to Cuba and this visit is expected to open up gates of opportunity for both the countries in exchanging their studies and research. As far as Cuba is concerned it has large variety of plants and cereals which have been developed through biotechnology and in order to gain from the experience of Cuba, Thailand is co-operating with it in this field. With regards to the development Thai scientists have undertaken researches on food and herbal studies in Cuba and in order to gain expertise have also undertaken a visit to Cuba’s Cancer Research Institute. It seems Thailand is all set to develop itself in the field of biotechnology.

Source:
http://www.biotechblog.org/rss.xml

05-06-2012 21:47 Biotech Video

Follow this link:
Biotech Video: The Wonderful Wizarding World of Biotechnology - Video

Scientific American to unveil the most comprehensive country-by-country comparison of biotechnology-innovation capacity at the BIO International Convention As athletes around the world prepare to travel to London for the 2012 Olympic Games, Scientific American gets set to unveil the worlds premiere performers in biotechnology through its 4th Annual Worldview Report and Scorecard.

This summer, more than 200 countries will parade their best of the best in the opening ceremonies in London, as Scientific American celebrates the leaders in biotechnology and, simultaneously, encourages countries seeking to expand their biotechnology-innovation capacity.

The parallels between the Olympics and biotechnology run even more deeply, including variations in rules around the world impacting performances. At the 1972 Munich games, for example, a last-minute rule change banned gold medal-favorite Bob Seagrens vaulting pole, forcing him to compete with unfamiliar equipment, although he still fought his way to a silver medal. Similarly, champions in biotechnology must find ways to perform under the pressure of shifting rules in different lands. For instance, some biotechnology crops can be planted in certain countries but not in others, and pharmaceutical regulators often talk about harmonization more than they achieve it. In the end, all players in the biotechnology industry could benefit from Seagrens never-give-up attitude.

As the world of biotechnology evolves, so does the Scientific American Worldview Scorecard. This year, 50 countries will be included in the index and there is a new metric that measures a countrys policy climate and stability. In addition, the protection of intellectual property (IP) and its impact on biotechnology innovation is explored in-depth. This years Scorecard also examines data in some new areas, including collaboration and medical tourism, which shows the interactive nature of a range of elements related to a countrys capabilities for encouraging biotechnology innovation.

Based on the past four years of data gathering, Scientific American can now start looking across time at trends in country scores and rankings, as well as the changing dynamics of the biotechnology industry since the economic crisis that started in 2007.

The Scientific American Worldview Report and Scorecard will use its four-year comparison of overall scores and country rankings to highlight the competitive nature of the biotechnology industry. In the past four years, Scientific American has added countries, incorporated new metrics and adjusted the methodology to improve the comparative power of this index. Despite the evolution of the Scorecards techniques, we can analyze the performance of countries over time to reveal some consistencies as well as some volatility, and explore ongoing trends by comparing results year-over-year.

Beyond the countries that climb our Scorecard podium, this years version places more emphasis than ever on the value of smaller companies and countries with less mature biotechnology industries. The breadth of this industry and its ongoing expansion makes it possible for a wide range of players to compete, especially ones who make the best of their inherent capabilities, such as natural resources, or team up with other players around the world.

Which country will win gold in greatest public company revenues? Which country will reign supreme for most public companies overall? Which country has the strongest patent protection? Attend the BIO International Convention Super Session, and find out by grabbing this years report.

Read more from the original source:
Going for the Biotechnology Gold

NEW YORK, June 5, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Biotechnology Reagents Industry

http://www.reportlinker.com/p098414/Global-Biotechnology-Reagents-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_

This report analyzes the worldwide markets for Biotechnology Reagents in US$ Million by the following Product Segments: Cell/Tissue Culture Reagents, DNA Sequencing/Synthesis Reagents, Electrophoresis Reagents, Flow Cytometry Reagents, Immunoassay Reagents, Liquid Chromatography Reagents, Polymerase Chain Reaction Reagents, and Protein Synthesis Reagents. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Latin America. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 267 companies including many key and niche players such as Abbott Diagnostics, Beckman Coulter, Inc., Becton Dickinson and Company, BioMrieux SA, EMD Biosciences, Inc., EMD Millipore Corporation, Fitzgerald Industries International, GE Healthcare, Life Technologies Corporation, Ortho-Clinical Diagnostics, PerkinElmer, Inc., Promega Corporation, Roche Diagnostics Ltd., Siemens Healthcare Diagnostics, Inc., and Sigma - Aldrich. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

To order this report:

In Vitro Diagnostic Industry: Global Biotechnology Reagents Industry

More Market Research Report

Check our Industry Analysis and Insights

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com

View post:
Global Biotechnology Reagents Industry

NEW YORK, June 5, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global Marine Biotechnology Industry

http://www.reportlinker.com/p080467/Global-Marine-Biotechnology-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biotechno

This report analyzes the Global markets for Marine Biotechnology in US$ Million by the following Product Segments: Marine Biomaterials, Marine Bioactive Substances, and Others. The major End-Use Applications analyzed are Industrial Products, Health Care/Biotechnology, Consumer Products, Public Services & Infrastructure, and Others. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for this market. The report profiles 87 companies including many key and niche players such as Aker BioMarine ASA, Ashland Inc., CP Kelco US, Inc., Cyanotech Corp., Elan Corp, FMC Corp., FMC Biopolymers AS, GlycoMar Ltd., Lonza Group Ltd., MariCal, Marinova, Mera Pharmaceuticals Inc., New England Biolabs Inc., PharmaMar S.A, PML Applications Ltd., Prolume Ltd., Royal DSM N.V, Sea Run Holdings Inc., and Tequesta Marine Biosciences. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

To order this report:

Biotechnology Industry: Global Marine Biotechnology Industry

More Market Research Report

Check our Industry Analysis and Insights

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com US: (805)-652-2626 Intl: +1 805-652-2626

Read the original:
Global Marine Biotechnology Industry

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Lando and Anastasi, LLP (L&A) today announced that Julie Gottselig, Dominic Yee, and Austin Kim have joined the firm.

The Cambridge-based intellectual property law firm, one of the largest IP firms in New England, continues its steady growth in response to strong client demand for high quality and responsive intellectual property legal services. The L&A biotechnology and pharmaceutical practice will expand with the addition of Julie Gottselig and Dominic Yee; and Austin Kim will join the firms electrical and computer science practice.

Julie Gottselig is an Associate at L&A. She focuses her practice on patent prosecution and counseling in the areas of biotechnology, pharmaceuticals, molecular biology, biochemistry, medical devices, and related fields. Prior to joining L&A, she was an Associate at McCarter & English, LLP in Boston. Julie is registered to practice before the United States Patent and Trademark Office.

Julie graduated from New England School of Law, summa cum laude, where she was the valedictorian of her class and recipient of the Dean Arthur W. MacLean Award for academic excellence. She received a Ph.D. in Neuroscience from the University of Iowa; she completed her post-doctoral fellowship at Harvard Medical School and Brigham & Womens Hospital; and she was a post-doctoral researcher at the Institute of Pharmacology & Toxicology, University of Zurich. Julie received her B.A. in Psychology from Colorado College. Prior to entering intellectual property law, Julie authored numerous peer-reviewed scientific research articles published in leading journals, and has received several research awards, including postdoctoral fellowship awards from the National Institute of Mental Health and the National Heart, Lung, and Blood Institute.

Dominic Yee is a Technology Specialist at L&A, and focuses his practice on patent prosecution, diligence and counseling in the areas of areas of biotechnology, pharmaceuticals, and chemistry.

Dominic received a Ph.D. in Chemistry from Columbia University, and he completed his post-doctoral fellowship with Nobel laureate Roger Tsien at the Howard Hughes Medical Institute at University of California San Diego (UCSD). Dominic received his B.S. in Chemistry and Biochemistry, magna cum laude, from UCSD. He attends Suffolk University Law School. Prior to entering intellectual property law, Dominic was a Scientist at Vertex Pharmaceuticals, where he worked on solid dosage form development and drug delivery technologies.

We are excited that Julie and Dominic have joined the life sciences team at L&A, and welcome the technological expertise they bring to both the biological and chemical aspects of our practice, commented Louis Myers, a Partner at the firm.

Austin Kim is an Associate at L&A. He focuses his practice on patent prosecution in the areas of computer science, electrical engineering, mechanical engineering, and medical devices. Prior to joining L&A, he was an Associate at Fish & Richardson in Boston. Austin is registered to practice before the United States Patent and Trademark Office.

Austin graduated from Boston College Law School. He received an M.Eng. and S.B. in Electrical Engineering and Computer Science from the Massachusetts Institute of Technology.

Read more from the original source:
Lando & Anastasi, LLP Expands Biotechnology/Pharmaceutical and Electrical/Computer Patent Teams